Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biopharmaceuticals
Johnson & Johnson Extends Tender Offer for Omrix Biopharmaceuticals, Inc.
January 10th, 2009
Johnson & Johnson (NYSE:JNJ) announced it has extended its previously announced cash tender offer, through its wholly-owned subsidiary, Binder Merger Sub, Inc., for all outstanding shares of common stock of Omrix Biopharmaceuticals, Inc. (NASDAQ:OMRI) until 12:00 midnight (Eastern time), on Dec. 26, 2008, unless further extended. The tender offer was originally scheduled to expire at 12:00 midnight (Eastern time) on Dec. 23, 2008. All other terms and conditions of the tender offer remain unchanged. As previously disclosed, the conditions to the tender offer relating to Israeli antitrust approval and other regulatory approvals have been satisfied. The depositary for the...
Source: Law & Health Weekly (2009-01-10)
|
